Tinicev Tablet 400 mg contains Imatinib Mesylate, a well-established targeted anticancer medicine belonging to the class of tyrosine kinase inhibitors (TKIs). It is primarily used in the management of specific cancers and hematological malignancies driven by abnormal tyrosine kinase activity. Tinicev Tablet 400 mg works by selectively blocking the enzymes that promote uncontrolled growth and survival of cancer cells, thereby slowing disease progression and improving clinical outcomes.

Therapeutic Class

Antineoplastic agent / Tyrosine kinase inhibitor

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Tinicev Tablet 400 mg is indicated for the treatment of:

• Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive (Ph+), in chronic phase, accelerated phase, or blast crisis

• Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

• Gastrointestinal Stromal Tumors (GIST) that are unresectable, recurrent, or metastatic

• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) associated with PDGFR gene rearrangements

• Aggressive systemic mastocytosis without the D816V mutation

• Hypereosinophilic syndrome and chronic eosinophilic leukemia

Pharmacology

Imatinib Mesylate exerts its therapeutic effect by selectively inhibiting several tyrosine kinases, including BCR-ABL, c-KIT, and platelet-derived growth factor (PDGF) receptors. These kinases play a crucial role in intracellular signaling pathways that regulate cell growth and survival. By blocking these enzymes, Tinicev Tablet 400 mg suppresses the proliferation of malignant cells while having comparatively minimal effects on normal cells.

Dosage and Administration

• Tinicev Tablet 400 mg should be taken orally with food and a full glass of water to reduce gastrointestinal irritation.

• The usual adult dose is determined by the treating physician based on the disease indication, patient response, and tolerability.

• In many cases, 400 mg once daily is used, though higher or divided doses may be required in certain conditions.

• Treatment is often long-term, and patients should not discontinue therapy without medical advice.

Contraindications

Tinicev Tablet 400 mg is contraindicated in patients with:

• Known hypersensitivity to Imatinib Mesylate or any excipients of the formulation

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Commonly reported side effects include:

• Nausea, vomiting, and diarrhea

• Fluid retention and edema

• Muscle cramps and musculoskeletal pain

• Fatigue and dizziness

• Skin rash and pruritus

• Abdominal discomfort

Most adverse effects are manageable with dose adjustment or supportive care under medical supervision.

Drug Interactions

• Concomitant use with strong CYP3A4 inhibitors or inducers may alter Imatinib plasma levels.

• Caution is advised with anticoagulants, certain antibiotics, antifungals, and anticonvulsants.

• Patients should inform their healthcare provider about all medications they are taking.

Pregnancy and Lactation

Tinicev Tablet 400 mg is not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus. Effective contraception should be used during treatment. Breastfeeding should be discontinued, as Imatinib may be excreted in breast milk.

Precautions and Warnings

• Regular monitoring of complete blood count, liver function, and renal function is advised.

• Use with caution in patients with cardiac disease or fluid retention.

• Sudden discontinuation may worsen disease control.

Storage Conditions

Store below 25°C in a dry place. Protect from light and moisture. Keep out of reach of children.